Role of the CD200-CD200R axis during homeostasis and neuroinflammation

G Manich, M Recasens, T Valente, B Almolda… - Neuroscience, 2019 - Elsevier
Microglia are considered to be the resident macrophages of the CNS and main effector of
immune brain function. Due to their essential role in the regulation of neuroinflammatory …

Immune privilege: the microbiome and uveitis

C Mölzer, J Heissigerova, HM Wilson… - Frontiers in …, 2021 - frontiersin.org
Immune privilege (IP), a term introduced to explain the unpredicted acceptance of allogeneic
grafts by the eye and the brain, is considered a unique property of these tissues. However …

3K3A-activated protein C prevents microglia activation, inhibits NLRP3 inflammasome and limits ocular inflammation

D Palevski, G Ben-David, Y Weinberger… - International Journal of …, 2022 - mdpi.com
3K3A-Activated Protein C (APC) is a recombinant variant of the physiological anticoagulant
APC with pleiotropic cytoprotective properties albeit without the bleeding risks. The anti …

Pembrolizumab administration associated with posterior uveitis

MT Aaberg, TM Aaberg Jr - Retinal Cases and Brief Reports, 2017 - journals.lww.com
Purpose: To describe the development of uveitis and retinal vasculitis in association with
pembrolizumab treatment for metastatic uveal melanoma. Methods: A case report and a brief …

[HTML][HTML] Blood-retina barrier dysfunction in experimental autoimmune uveitis: the pathogenesis and therapeutic targets

J Kim, J Chun, M Ahn, K Jung, C Moon… - Anatomy & Cell …, 2022 - synapse.koreamed.org
Experimental autoimmune uveitis (EAU), an animal model of human uveitis, is characterized
by infiltration of autoimmune T cells in the uvea as well as in the retina of susceptible …

Therapeutic potential of anti-CD137 (4-1BB) monoclonal antibodies

DS Vinay, BS Kwon - Expert opinion on therapeutic targets, 2016 - Taylor & Francis
Introduction: 4-1BB (CD137) is an important T-cell stimulating molecule. The 4-1BB mAb or
its variants have shown remarkable therapeutic activity against autoimmunity, viral …

Advancements in understanding immunogenicity of biotherapeutics in the intraocular space

E Wakshull, V Quarmby, HC Mahler, H Rivers, D Jere… - The AAPS journal, 2017 - Springer
Therapeutic breakthroughs in a number of retinal degenerative diseases have come about
through the development of biotherapeutics administered directly into the eye. As a …

Colitis in a transgenic mouse model of autoimmune uveitis may be induced by neoantigen presentation in the bowel

C Moelzer, YH Liu, E Muckersie, IP Klaska… - Scientific Reports, 2023 - nature.com
Undifferentiated uveitis (intraocular inflammation, IOI) is an idiopathic sight-threatening,
presumed autoimmune disease, accountable for~ 10% of all blindness in the developed …

Targeted delivery of autoantigen to dendritic cells prevents development of spontaneous uveitis

IP Klaska, T Yu, R Fordyce, K Kamoi… - Frontiers in …, 2023 - frontiersin.org
Restoration of immunological tolerance to self antigens has been a major drive in
understanding the mechanisms of, and developing new treatments for, autoimmune and …

KS23, a novel peptide derived from adiponectin, inhibits retinal inflammation and downregulates the proportions of Th1 and Th17 cells during experimental …

T Niu, L Cheng, H Wang, S Zhu, X Yang, K Liu… - Journal of …, 2019 - Springer
Background Uveitis is a potentially sight-threatening form of ocular inflammation that affects
the uvea in the wall of the eye. Currently available treatments for uveitis have exhibited …